

## Formulary Council Meeting Minutes

March 18, 2019

Present: Formulary Council Chair Kevin Wilson, ND; Council Members: Justin Bednar, RPh; Natalie Gustafson, PharmD; Dohn Kruschwitz, MD; Lissa McNiel, ND; Adam Alani, PhD; Carmen Ionescu, MD, ND; Joanna Tucker Davis, AAG, Legal Counsel and Mary-Beth Baptista, Executive Director.

Meeting started at 9:54 am

**Ozone Therapy:** Dr. K. Wilson brought up that if ND's use Ozone Therapy ND's will need to be trained, like chelation. Dr. C. Ionescu would like to have a sub-committee to talk more in-depth research on Ozone Therapy and then bring the information back to the Formulary Committee to discuss and bring their recommendation to the Board. The sub-committee to research safety, usage and concentration of Ozone Therapy.

Dr. K. Wilson made a motion to create a sub-committee for rule making on Ozone Therapy. Dr. L. McNiel seconded, The Formulary Committee approved unanimously. Committee members will be Dr. C. Ionescu, Dr. L. McNiel and Dr. A. Alani. Dr. K. Wilson will have minimal input because of his knowledge and usage of Ozone Therapy in his practice. Dr. C. Ionescu will look at the benefits/adverse outcome. Dr. L. McNiel will research peer review articles. Dr. A. Alani will review administration of Ozone. MB. Baptista will review other legislation in the state/legal part.

**Compounding Pharmacy & Licensing:** The Oregon Board of Pharmacy is working on rules and have the rules completed by September 2019 to coincide with the USP and FDA changes. Changes and restrictions with compounding are happening this year. Sterile items would be injectables, eye drops, IVs vs IMs basically anything introduced in that way. Non-Steriles like capsules and creams. The finale verdict will be in June and then pharmacies will have 6 months. This will be a complete overhaul of how compounding is done. Structural requirements, hospitals will not have the structural requirements until the rule changes because of budget approvals. There could be restricted access and dating to compounding items. Different restrictions will be coming from USP, FDA and the Oregon Pharmacy Board for steriles. FDA is regulating what can and cannot be compounded. USP is where our rules come from. The Oregon Board of Pharmacy is changing its rules to match USP by December 1.

**Out of State Prescribing:** Pharmacist can only mail prescriptions to patients in states the pharmacist is licensed.

**Approval of Formulary Council Minutes:** Dr. D. Kruschwitz made a motion to approve the minutes from the September 24, 2018 meeting, Dr. K. Wilson seconded, The Formulary Committee approved unanimously.

**Board Recruitment-Public Member:** Dr. L. McNeil's board term is up and the position will need to be filled. The Formulary Council members reviewed the applications received and MB. Baptista informed the Formulary Council the Board's preference. The Board also needs a public member to sit on the Board and MB. Baptista asked Dr. A. Alani if his wife who is a pharmacist is she is interested in the position to apply.

**Investigator 2 Position:** The Board's investigator resigned and the Board is currently recruiting for a new investigator. Dr. J. Gibbons, chair of the Board and public member, J. Freedman will be involved in the interview process.

**Legislation:** The Board's 2019-2021 budget passed legislation. The Board received an increase in funds for a new database and IT person.

The peer review committee was set up about 20 years ago before the Board was set up as it is now. The association, OANP, wrote a supportive letter and attended the legislative meeting in support to remove the peer review process. The rules that are in place around peer review will need to be changed.

The next Formulary Council meeting is September 23, 2019 at 9:30 am.

Meeting adjourned at 11:40 am

# Formulary Council Meeting Minutes

September 23, 2019

Present: Formulary Council Acting Chair Dohn Kruschwitz, MD; Council Members: Justin Bednar, RPh; Natalie Gustafson, PharmD; Will McClatchey, RPh; Adam Alani, PhD; Carmen Ionescu, MD, ND; Bill Walter, ND; Mary-Beth Baptista, Executive Director.

Absent: Chair Kevin Wilson, ND

Meeting started at 9:30 am

Welcome new Formulary Council Members: Will McClatchey, RPh and Bill Walter, ND and returning member Natalie Gustafson, PharmD.

**Approval of Formulary Council Minutes:** March 18, 2019 Formulary Council Meeting Minutes approved.

**Council Member Discussion/Sub-Formulary Committee Draft Revisions: OAR 850-060-0212**

The Formulary Sub-Committee approved draft rule for OAR 850-060-0212 Injection Therapy as developed by the Ozone Therapy subcommittee, and discussed submitting the approved draft to the Board to file for permanent rule change. Changes to the rule include, but are not limited to additional training and continuing education prior to engaging in injection / ozone therapy. Limits Chelation and Ozone Therapy administered by the ND only.

Going into executive session at 10:14 am to discuss legal advice. All members are present. Administering Ozone is not prescribing.

Back into public session at 10:18 am. All members are present.

Dr. B. Walter made a motion to send OAR 850-060-0212 to the Board for rule making. Dr. D. Kruschwitz seconded. The Board approved unanimously.

**Mandatory PDMP registration:** MB. Baptista reported ND's have a high percentage of registration/compliance.

MDMA/MAPS: Clinical trials continuing, for PTSD and other conditions. Oregon may be adopting laws on usage for therapeutic purposes.

The Formulary Council will start working on guidelines on pharmacy CE.

The next Formulary Council meeting is March 9, 2020 at 9:30 am.

Meeting adjourned at 11:34 am